AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
Log in

NASDAQ:AVDLAvadel Pharmaceuticals Stock Price, Forecast & News

$8.06
-0.34 (-4.05 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.80
Now: $8.06
$8.46
50-Day Range
$7.70
MA: $9.21
$11.75
52-Week Range
$1.53
Now: $8.06
$13.49
Volume761,200 shs
Average Volume880,180 shs
Market Capitalization$301.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More
Avadel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVDL
CUSIPN/A
Phone353-1485-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.22 million
Book Value$0.86 per share

Profitability

Net Income$-33,230,000.00

Miscellaneous

Employees144
Market Cap$301.85 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

How has Avadel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVDL stock has increased by 0.9% and is now trading at $8.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avadel Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Avadel Pharmaceuticals.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) announced its earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.25. The firm earned $12.24 million during the quarter, compared to the consensus estimate of $10.25 million. View Avadel Pharmaceuticals' earnings history.

What guidance has Avadel Pharmaceuticals issued on next quarter's earnings?

Avadel Pharmaceuticals updated its first quarter 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $8.35 million.

What price target have analysts set for AVDL?

6 Wall Street analysts have issued 12 month price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $6.00 to $18.00. On average, they expect Avadel Pharmaceuticals' share price to reach $11.92 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals.

Has Avadel Pharmaceuticals been receiving favorable news coverage?

Media coverage about AVDL stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAvadel Pharmaceuticals.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 6,500,000 shares, an increase of 47.7% from the April 15th total of 4,400,000 shares. Based on an average daily volume of 730,600 shares, the short-interest ratio is currently 8.9 days. Approximately 18.8% of the shares of the stock are short sold. View Avadel Pharmaceuticals' Current Options Chain.

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and China Unicom (Hong Kong) (CHU).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
  • Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
  • Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (9.55%), Cowen AND Company LLC (4.05%), VR Adviser LLC (2.82%), Invesco Ltd. (1.96%), Tekla Capital Management LLC (1.51%) and Driehaus Capital Management LLC (1.31%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View institutional ownership trends for Avadel Pharmaceuticals.

Which institutional investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Tekla Capital Management LLC, UBS Group AG, and Investors Asset Management of Georgia Inc. GA ADV. View insider buying and selling activity for Avadel Pharmaceuticals.

Which institutional investors are buying Avadel Pharmaceuticals stock?

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Cowen AND Company LLC, VR Adviser LLC, Invesco Ltd., Driehaus Capital Management LLC, Ghost Tree Capital LLC, Arlington Capital Management Inc., and Bailard Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, and Michael S Anderson. View insider buying and selling activity for Avadel Pharmaceuticals.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $8.06.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $301.85 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.